EpiVax, Inc. - Informatics and Immunology
  • Our Company
    • Company Overview
    • Corporate Responsibility
    • Mission, Vision & Values
    • Team
    • Careers
    • Contact Us
  • Pipeline
    • Pipeline Overview
    • BioDefense Vaccines
    • Tregitope: Immunomodulation Power Tool
    • Deimmunization Projects
  • Vaccine Services
    • Vaccine Services
    • iVAX: Web-based Vaccine Design
    • PreVAX Analysis
    • EpiCC
  • Immunogenicity Assessment
    • Immunogenicity Assessment Overview
    • ISPRI Web-based Immunogenicity Assessment
    • PreDeFT Analysis
    • High Throughput Immunogenicity Analysis
    • PANDA Screening
    • ISPRI for Host Cell Proteins
    • Deimmunization
    • Trusted Expert Advice (TEA) Consulting Services
  • Lab Services
    • Lab Services Overview
    • HLA Binding Assays
    • T Cell Assays
  • Press Room
    • Press Room
    • Events
      • Webinars
    • Publication & Poster Search
    • Client Testimonials
    • Thinking Out Loud (Blog)
    • Recipes For Success (Podcast)
  • Contact Us
Select Page
Comprehensive Assessment of Immunogenicity Risk of Host Cell Proteins in Biologics Using in Silico and in Vitro Methods

Comprehensive Assessment of Immunogenicity Risk of Host Cell Proteins in Biologics Using in Silico and in Vitro Methods

by Elena Iemma | May 1, 2023

Comprehensive Assessment of Immunogenicity Risk of Host Cell Proteins in Biologics Using in silico and in vitro Methods
Multi-Factored Immunogenicity Risk Assessment Approach for Bispecific Immune-Cell Engagers

Multi-Factored Immunogenicity Risk Assessment Approach for Bispecific Immune-Cell Engagers

by Elena Iemma | May 1, 2023

Multi-Factored Immunogenicity Risk Assessment Approach for Bispecific Immune Cell-Engagers 
Tumor homology with self as a biomarker for response to checkpoint inhibitor therapy

Tumor homology with self as a biomarker for response to checkpoint inhibitor therapy

by Corey Iacono | Nov 17, 2022

EpiVaxTx_SITC22_Melanoma_28Oct22_56Wx31.5H    
A SARS-CoV-2 T cell epitope homologous to a validated human Treg epitope (Tregitope) suppresses CD4 and CD8 T cell memory responses

A SARS-CoV-2 T cell epitope homologous to a validated human Treg epitope (Tregitope) suppresses CD4 and CD8 T cell memory responses

by Corey Iacono | Aug 29, 2022

A SARS-CoV-2 T cell epitope homologous to a validated human Treg epitope (Tregitope) suppresses CD4 and CD8 T cell memory responses Shah Md. Shahjahan Miah, Andres Gutierrez, Sandra Lelias, Christine M. Boyle, Lenny Moise, Anne S. De Groot EpiVax Inc, Providence, RI...
Vaccine Optimization by Identification, Characterization, and Downselection of Human T Cell Epitopes from Plasmodium falciparum Circumsporozoite Protein.

Vaccine Optimization by Identification, Characterization, and Downselection of Human T Cell Epitopes from Plasmodium falciparum Circumsporozoite Protein.

by Annie De Groot | Nov 23, 2019

Vaccine Optimization by Identification, Characterization, and Downselection of Human T Cell Epitopes from Plasmodium falciparum Circumsporozoite Protein.
« Older Entries

Recent Posts

  • Streamlining Generic Drug Immunogenicity Evaluation: EpiVax’s “PANDA” Approach
  • Throw Down a Challenge
  • EpiVax Birthday Cake Alert! | Fall ’23 Travel Schedule
  • Lab Day at the Beach 2023 *Pictures!*
  • High Throughput Immunogenicity Analysis

Categories

  • EpiVax Immunoncology
  • Events
  • Featured
  • News
  • Recipes for Success – Vlog
  • Thinking Out Loud -Blog
  • Uncategorized
  • Webinars

Discover

  • Vaccine Services
  • Immunogenicity Assessment
  • Deimmunization
  • Lab Services
  • Pipeline

About

  • Our Company
  • Press Room
  • Events
  • Publication & Poster Search
  • Thinking Out Loud (Blog)
  • Contact Us

Connect

© 2023 EpiVax, Inc. – Informatics and Immunology, All rights reserved. Privacy Policy • 188 Valley Street, Suite 424, Providence, RI 02909 • ph: 401.272.2123 • fax: 401.272.7562